Effects of Omega-3 Supplementation on Motor Performance and Bone Turnover Markers in Women: A Pilot Study (OMEGA3-FEMALE)
Effects of Omega-3 Fatty Acid Supplementation on Selected Measures of Motor Performance and Bone Turnover Markers in Female Soccer Players and Women With Low Physical Activity: A Randomized, Double-Blind, Placebo-Controlled - Pilot Study
The aim of this pilot study is to assess the effects of 10 weeks of omega-3 fatty acid supplementation on selected motor performance parameters, bone turnover markers, regulators of bone remodeling, and bone mineral density in female soccer players and women with low levels of physical activity. Changes in the erythrocyte omega-3 fatty acid profile, including EPA and DHA levels and the Omega-3 Index, will also be assessed, along with potential differences in response to supplementation between the two populations.
This will be an interventional, randomized, double-blind, placebo-controlled study. A total of 40 women aged 18-35 years will be enrolled: 20 female soccer players and 20 women with low levels of physical activity. Within each population, participants will be randomly allocated in a 1:1 ratio to the omega-3 supplementation or placebo group, yielding four parallel study groups. Over 10 weeks, participants assigned to omega-3 will take three capsules daily providing 1,677 mg of EPA and 687 mg of DHA. Participants assigned to placebo will take three capsules daily providing a total of 3,000 mg of MCT oil.
Assessments will be performed at three time points: T0 (baseline, before the start of supplementation), T1 (after 5 weeks of supplementation), and T2 (after 10 weeks of supplementation). Assessments will include handgrip strength, back muscle strength, lower-limb power assessed by vertical jump testing, bone turnover markers and regulators of bone remodeling, body composition and bone mineral density measured by DXA, the erythrocyte fatty acid profile, selected hormonal parameters, and dietary intake.
The effects of supplementation will be evaluated by assessing changes in the measured parameters at weeks 5 and 10 relative to baseline (T0). The magnitude of these changes will also be compared between the omega-3 and placebo groups, taking participants' level of physical activity into account.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are involved in numerous physiological processes, including regulation of inflammatory responses and the functioning of skeletal muscle and bone tissue. However, scientific evidence regarding the effects of omega-3 supplementation on physical performance and bone metabolism remains inconclusive, particularly among physically active women. This pilot study will assess responses to a controlled supplementation intervention in female soccer players and women with low levels of physical activity.
The study is interventional, randomized, placebo-controlled, and double-blind. It will include 40 women aged 18-35 years: 20 female soccer players and 20 women with low levels of physical activity. Randomization will be conducted separately within each population in a 1:1 ratio, resulting in four groups: female soccer players receiving omega-3, female soccer players receiving placebo, women with low levels of physical activity receiving omega-3, and women with low levels of physical activity receiving placebo. Treatment allocation will remain concealed from participants, outcome assessors, and data analysts until study completion and database lock.
For 10 weeks, participants in the active supplementation groups will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily, providing 3,000 mg of concentrated fish oil, including 1,677 mg of EPA and 687 mg of DHA. Participants in the placebo groups will take three NOW Foods MCT Oil 1000 mg capsules daily, providing 3,000 mg of MCT oil. Supplement adherence and any adverse events will be monitored using participant records, contact with the research team, and counts of unused capsules.
Assessments will be conducted at three time points: T0 (baseline, before supplementation), T1 (after 5 weeks of supplementation), and T2 (after 10 weeks of supplementation). The T0 assessment will establish baseline values for the measured parameters, providing a reference for evaluating changes during the intervention. At each time point, motor performance will be assessed using handgrip strength, back muscle strength, and vertical jump tests. Body composition and bone mineral density will be assessed by dual-energy X-ray absorptiometry (DXA). Blood measurements will include the erythrocyte fatty acid profile and Omega-3 Index, estradiol and progesterone, and bone metabolism markers P1NP, CTX, OPG, RANKL, SOST, and DKK-1. Data on health status, menstrual cycle, hormonal contraception, physical activity, dietary intake, and anthropometry will also be collected.
The primary scientific aim is to assess the effects of omega-3 fatty acid supplementation compared with placebo on selected motor performance parameters, markers of bone turnover and remodeling, and bone mineral density. Intervention effects will be evaluated by comparing values at T1 and T2 with baseline values at T0, including comparisons between the omega-3 and placebo groups. Supplementary analyses will assess changes in EPA and DHA levels and potential differences in response between female soccer players and women with low levels of physical activity.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Aleksandra Aneta Sarachman, MSc
- Número de teléfono: +48 882 521 877
- Correo electrónico: aleksandra.sarachman@awf.wroc.pl
Ubicaciones de estudio
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polonia, 51-612
- Reclutamiento
- Wroclaw University of Health and Sport Sciences
-
Contacto:
- Aleksandra Sarachman, MSc
- Número de teléfono: +48 882 521 877
- Correo electrónico: aleksandra.sarachman@awf.wroc.pl
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Female soccer players:
- Female sex, age 18-35 years.
- Regular sports training for more than 10 hours per week.
- Active participation in league competitions.
- No medical contraindications to participation.
- No injury resulting in a training interruption longer than 2 weeks during the 3 months before the study.
- Written informed consent to participate, undergo blood collection, and have laboratory tests performed.
Women with low levels of physical activity:
- Female sex, age 18-35 years.
- Physical activity below 150 minutes per week.
- Body mass index (BMI) between 18.5 and 24.9 kg/m².
- No medical contraindications to participation.
- Written informed consent to participate, undergo blood collection, and have laboratory tests performed.
Exclusion Criteria:
- Pregnancy or breastfeeding.
- Use of supplements containing omega-3 fatty acids within the 3 months before the study.
- Allergy or hypersensitivity to fish, fish oil, gelatin, or other ingredients of the active supplement or placebo.
- Diseases or use of medications that may substantially affect lipid metabolism, muscle function, or bone metabolism.
- Neurological disorders.
- Bleeding disorders or treatment considered by a physician to increase the risks associated with supplementation or blood sampling.
- Injury or symptoms that prevent safe performance of motor tests.
- Other contraindications identified during medical screening.
- Failure to provide written informed consent to participate, undergo blood collection, and have the planned analyses performed.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Arm 1 - Female Soccer Players: Omega-3
Female soccer players actively participating in league competitions and training for more than 10 hours per week will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily for 10 weeks. |
Participants will take three softgel capsules daily for 10 weeks. The daily dose will provide 3,000 mg of concentrated fish oil containing 2,457 mg of omega-3 fatty acids, including 1,677 mg of EPA and 687 mg of DHA. |
|
Comparador de placebos: Arm 2 - Female Soccer Players: Placebo
Female soccer players actively participating in league competitions and training for more than 10 hours per week will take three NOW Foods MCT Oil 1000 mg capsules daily for 10 weeks. |
Participants will take three softgel capsules daily for 10 weeks, providing 3,000 mg of MCT oil per day. The placebo contains neither EPA nor DHA. |
|
Experimental: Arm 3 - Women With Low Levels of Physical Activity: Omega-3
Women with low levels of physical activity (less than 150 minutes per week) will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily for 10 weeks. |
Participants will take three softgel capsules daily for 10 weeks. The daily dose will provide 3,000 mg of concentrated fish oil containing 2,457 mg of omega-3 fatty acids, including 1,677 mg of EPA and 687 mg of DHA. |
|
Comparador de placebos: Arm 4 - Women With Low Levels of Physical Activity: Placebo
Women with low levels of physical activity (less than 150 minutes per week) will take three NOW Foods MCT Oil 1000 mg capsules daily for 10 weeks. |
Participants will take three softgel capsules daily for 10 weeks, providing 3,000 mg of MCT oil per day. The placebo contains neither EPA nor DHA. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Handgrip Strength
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Handgrip strength will be assessed using a T.K.K. 5001 dynamometer (Takei Scientific Instruments) at T0, T1, and T2. Changes after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Back Muscle Strength
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Back muscle strength will be measured using a T.K.K. 5402 dynamometer (Takei Scientific Instruments) at T0, T1, and T2. Changes after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Vertical Jump Performance
Periodo de tiempo: : T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Lower-limb power will be assessed using vertical jump testing with the OptoJump system (Microgate) at T0, T1, and T2. Changes in vertical jump results after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Serum P1NP Concentration
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Serum concentrations of the N-terminal propeptide of type I procollagen (P1NP), a marker of bone formation, will be determined by ELISA at T0, T1, and T2. Changes in P1NP concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Serum CTX Concentration
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Serum concentrations of the C-terminal telopeptide of type I collagen (CTX), a marker of bone resorption, will be measured at T0, T1, and T2. Changes in CTX concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Bone Mineral Density
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Whole-body bone mineral density (BMD) will be assessed by DXA using a Lunar iDXA scanner (GE HealthCare) at T0, T1, and T2. Changes in BMD after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Serum Osteoprotegerin Concentration
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Osteoprotegerin (OPG), a regulator of bone remodeling, will be measured in serum using ELISA at T0, T1, and T2. Changes in OPG concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Serum RANKL Concentration
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Receptor activator of nuclear factor kappa-B ligand (RANKL) will be measured in serum using ELISA at T0, T1, and T2. Changes in RANKL concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Serum Sclerostin Concentration
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Sclerostin (SOST) will be measured in serum using ELISA at T0, T1, and T2. Changes in SOST concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Serum DKK-1 Concentration
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Dickkopf-1 (DKK-1) protein will be measured in serum using ELISA at T0, T1, and T2. Changes in DKK-1 concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Erythrocyte EPA Content
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
The proportion of eicosapentaenoic acid (EPA) in the erythrocyte fatty acid profile will be determined by gas chromatography with flame ionization detection (GC-FID) at T0, T1, and T2. Changes in EPA content after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Erythrocyte DHA Content
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
The proportion of docosahexaenoic acid (DHA) in the erythrocyte fatty acid profile will be determined by gas chromatography with flame ionization detection (GC-FID) at T0, T1, and T2. Changes in DHA content after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in Omega-3 Index
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
The Omega-3 Index will be calculated from the combined proportion of EPA and DHA in the erythrocyte fatty acid profile at T0, T1, and T2. Changes in the Omega-3 Index after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
|
Change in the Erythrocyte Omega-6 to Omega-3 Ratio
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
The omega-6 to omega-3 fatty acid ratio will be derived from the erythrocyte fatty acid profile measured by GC-FID at T0, T1, and T2. Changes in the omega-6 to omega-3 ratio after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Dietary Intake
Periodo de tiempo: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Dietary intake will be assessed using a 72-item food frequency questionnaire and a 7-day food diary, including the intake of omega-3 fatty acids. Assessments will be conducted at T0, T1, and T2. Changes in dietary intake and omega-3 fatty acid consumption after 5 and 10 weeks of supplementation relative to baseline will be analyzed. |
T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Silla de estudio: Anna Książek, PhD, DSc, Department of Biological Principles of Physical Activity Wroclaw University of Health and Sport Sciences, Poland 35 Paderewskiego Avenue, 51-612 Wrocław,
Publicaciones y enlaces útiles
Publicaciones Generales
- Dou Y, Wang Y, Chen Z, Yu X, Ma D. Effect of n-3 polyunsaturated fatty acid on bone health: A systematic review and meta-analysis of randomized controlled trials. Food Sci Nutr. 2021 Nov 29;10(1):145-154. doi: 10.1002/fsn3.2655. eCollection 2022 Jan.
- Larrosa M, Gil-Izquierdo A, Gonzalez-Rodriguez LG, Alferez MJM, San Juan AF, Sanchez-Gomez A, Calvo-Ayuso N, Ramos-Alvarez JJ, Fernandez-Lazaro D, Lopez-Grueso R, Lopez-Leon I, Moreno-Lara J, Dominguez-Balmaseda D, Illescas-Quiroga R, Cuenca E, Lopez T, Montoya JJ, Rodrigues-de-Souza DP, Carrillo-Alvarez E, Casado A, Rodriguez-Donate B, Porta-Oliva M, Santiago C, Iturriaga T, De Lucas B, Solaesa AG, Montero-Lopez MDP, Benitez De Gracia E, Veiga-Herreros P, Munoz-Lopez A, Orantes-Gonzalez E, Barbero-Alvarez JC, Cabeza-Ruiz R, Carnero-Diaz A, Sospedra I, Fernandez-Galvan LM, Martinez-Sanz JM, Martin-Almena FJ, Perez M, Guerra-Hernandez EJ, Lopez-Samanes A, Sanchez-Oliver AJ, Dominguez R. Nutritional Strategies for Optimizing Health, Sports Performance, and Recovery for Female Athletes and Other Physically Active Women: A Systematic Review. Nutr Rev. 2025 Mar 1;83(3):e1068-e1089. doi: 10.1093/nutrit/nuae082.
- Gao J, Xie C, Yang J, Tian C, Zhang M, Lu Z, Meng X, Cai J, Guo X, Gao T. The Effects of n-3 PUFA Supplementation on Bone Metabolism Markers and Body Bone Mineral Density in Adults: A Systematic Review and Meta-Analysis of RCTs. Nutrients. 2023 Jun 19;15(12):2806. doi: 10.3390/nu15122806.
- Fernandez-Lazaro D, Arribalzaga S, Gutierrez-Abejon E, Azarbayjani MA, Mielgo-Ayuso J, Roche E. Omega-3 Fatty Acid Supplementation on Post-Exercise Inflammation, Muscle Damage, Oxidative Response, and Sports Performance in Physically Healthy Adults-A Systematic Review of Randomized Controlled Trials. Nutrients. 2024 Jun 27;16(13):2044. doi: 10.3390/nu16132044.
- Jager R, Heileson JL, Abou Sawan S, Dickerson BL, Leonard M, Kreider RB, Kerksick CM, Cornish SM, Candow DG, Cordingley DM, Forbes SC, Tinsley GM, Bongiovanni T, Cannataro R, Campbell BI, Arent SM, Stout JR, Kalman DS, Antonio J. International Society of Sports Nutrition Position Stand: Long-Chain Omega-3 Polyunsaturated Fatty Acids. J Int Soc Sports Nutr. 2025 Dec;22(1):2441775. doi: 10.1080/15502783.2024.2441775. Epub 2025 Jan 15.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
Otros números de identificación del estudio
- OMEGA3-FEMALE-PILOT-2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data will not be shared with external researchers or deposited in public repositories, even after removal of direct identifiers. Access to the data will be restricted to authorized members of the research team. Study results will be published only in aggregate form, without disclosing participants' identities.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .